Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review)

Tang,Bo; Yong,Xin; Xie,Rui; Li,Qian-Wei; Yang,Shi-Ming

doi:10.3892/ijo.2014.2276

Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review)

Authors:
- Bo Tang
- Xin Yong
- Rui Xie
- Qian-Wei Li
- Shi-Ming Yang
View Affiliations

Affiliations: Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China, Department of Nuclear Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: January 24, 2014 https://doi.org/10.3892/ijo.2014.2276
Pages: 1023-1031

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vasoactive intestinal peptide receptors (VIPRs) are members of the G-protein-coupled receptor superfamily. These receptors are overexpressed in many common malignant tumors and play a major role in the progression and angiogenesis of a number of malignancies. Therefore, VIPRs may be a valuable target for the molecular imaging of tumors and therapeutic interventions. The specific natural ligand or its analogs can be labeled with a radionuclide and used for tumor receptor imaging, which could be used to visualize VIPR-related surface protein expression in vivo and to monitor the in vivo effects of molecular drugs on tumors. Moreover, the involvement of VIPRs in malignant transformation and angiogenesis renders them potential therapeutic targets for cancer treatment. A variety of VIP antagonists and cytotoxic VIP conjugates have been synthesized and evaluated for VIPR-targeted molecular therapy. The importance of VIPRs in tumor biology and the ability to predict responses to targeted therapy and monitor drug interventions suggest that VIP receptor-based imaging and treatment will be critical for the early diagnosis and management of cancer. Here, we review the current literature regarding VIPRs and their natural ligands and the involvement of VIPRs in tumor growth and angiogenesis, with an emphasis on the present use of VIPRs for the molecular imaging of tumors and therapies targeting VIPRs.

View Figures

View References

1.	Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 30:773–782. 2013.PubMed/NCBI
3.	Pluchino KM, Hall MD, Goldsborough AS, Callaghan R and Gottesman MM: Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 15:98–105. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Burris HA III: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
5.	Garanger E, Boturyn D and Dumy P: Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem. 7:552–558. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Tolmachev V: Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 14:2999–3019. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Kaklamani V and O’Regan RM: New targeted therapies in breast cancer. Semin Oncol. 31:20–25. 2004. View Article : Google Scholar
8.	Mankoff DA, Link JM, Linden HM, Sundararajan L and Krohn KA: Tumor receptor imaging. J Nucl Med. 49:S149–S163. 2008. View Article : Google Scholar
9.	Nunn AD: Molecular imaging and personalized medicine: an uncertain future. Cancer Biother Radiopharm. 22:722–739. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Mankoff DA: A definition of molecular imaging. J Nucl Med. 48:N18–N21. 2007.
11.	Sherwood NM, Krueckl SL and McRory JE: The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev. 21:619–670. 2000.PubMed/NCBI
12.	Said SI and Mutt V: Polypeptide with broad biological activity: isolation from small intestine. Science. 169:1217–1218. 1970. View Article : Google Scholar : PubMed/NCBI
13.	Piper PJ, Said SI and Vane JR: Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature. 225:1144–1146. 1970. View Article : Google Scholar : PubMed/NCBI
14.	Barbezat GO and Grossman MI: Intestinal secretion: stimulation by peptides. Science. 174:422–424. 1971. View Article : Google Scholar : PubMed/NCBI
15.	Gozes I, Fridkinb M, Hill JM and Brenneman DE: Pharmaceutical VIP: prospects and problems. Curr Med Chem. 6:1019–1034. 1999.PubMed/NCBI
16.	Gozes I and Furman S: VIP and drug design. Curr Pharm Des. 9:483–494. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Tsukada T, Horovitch SJ, Montminy MR, Mandel G and Goodman RH: Structure of the human vasoactive intestinal polypeptide gene. DNA. 4:293–300. 1985.
18.	Gozes I, Avidor R, Yahav Y, Katznelson D, Croce CM and Huebner K: The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21-6qter. Hum Genet. 75:41–44. 1987.PubMed/NCBI
19.	Davidson A, Moody TW and Gozes I: Regulation of VIP gene expression in general. Human lung cancer cells in particular. J Mol Neurosci. 7:99–110. 1996. View Article : Google Scholar : PubMed/NCBI
20.	Itoh N, Obata K, Yanaihara N and Okamoto H: Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature. 304:547–549. 1983. View Article : Google Scholar : PubMed/NCBI
21.	Bodner M, Fridkin M and Gozes I: Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc Natl Acad Sci USA. 82:3548–3551. 1985. View Article : Google Scholar : PubMed/NCBI
22.	Vandermeers A, Vandenborre S, Hou X, de Neef P, Robberecht P, Vandermeers-Piret MC and Christophe J: Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes. Eur J Biochem. 208:815–819. 1992. View Article : Google Scholar
23.	Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A and Vaudry H: Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 52:269–324. 2000.PubMed/NCBI
24.	Fahrenkrug J: VIP and PACAP. Results Probl Cell Differ. 50:221–234. 2010.
25.	Dickson L and Finlayson K: VPAC and PAC receptors: From ligands to function. Pharmacol Ther. 121:294–316. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L and Vaudry H: Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 61:283–357. 2009.PubMed/NCBI
27.	Muller JM, Debaigt C, Goursaud S, Montoni A, Pineau N, Meunier AC and Janet T: Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update. Peptides. 28:1655–1666. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Laburthe M, Couvineau A and Marie JC: VPAC receptors for VIP and PACAP. Recept Chann. 8:137–153. 2002. View Article : Google Scholar : PubMed/NCBI
29.	Couvineau A, Lacapere JJ, Tan YV, Rouyer-Fessard C, Nicole P and Laburthe M: Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. J Biol Chem. 278:24759–24766. 2003. View Article : Google Scholar
30.	Dickson L, Aramori I, McCulloch J, Sharkey J and Finlayson K: A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 51:1086–1098. 2006. View Article : Google Scholar
31.	Barrie AP, Clohessy AM, Buensuceso CS, Rogers MV and Allen JM: Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells. J Biol Chem. 272:19666–19671. 1997. View Article : Google Scholar
32.	Lelièvre V, Pineau N, Du J, Wen CH, Nguyen T, Janet T, Muller JM and Waschek JA: Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase. J Biol Chem. 273:19685–19690. 1998.PubMed/NCBI
33.	Delgado M and Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem. 274:31930–31940. 1999. View Article : Google Scholar
34.	Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, Sakaue M, Miyazaki J, Niwa H, Tashiro F, Yamamoto K, Koga K, Tomimoto S, Kunugi A, Suetake S and Baba A: Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA. 98:13355–13360. 2001. View Article : Google Scholar : PubMed/NCBI
35.	Jozsa R, Hollosy T, Nemeth J, Tamás A, Lubics A, Jakab B, Olah A, Arimura A and Reglödi D: Presence of PACAP and VIP in embryonic chicken brain. Ann NY Acad Sci. 1070:348–353. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Valdehita A, Carmena MJ, Collado B, Prieto JC and Bajo AM: Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul Pept. 144:101–108. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ and Prieto JC: Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol Cell Endocrinol. 302:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
38.	Sreedharan SP, Patel DR, Huang JX and Goetzl EJ: Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun. 193:546–553. 1993. View Article : Google Scholar : PubMed/NCBI
39.	Usdin TB, Bonner TI and Mezey E: Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 135:2662–2680. 1994.PubMed/NCBI
40.	Wei Y and Mojsov S: Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol. 8:811–817. 1996. View Article : Google Scholar
41.	Moller K and Sundler F: Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. Regul Pept. 63:129–139. 1996. View Article : Google Scholar : PubMed/NCBI
42.	Zeng N, Kang T, Lyu RM, Wong H, Wen Y, Walsh JH, Sachs G and Pisegna JR: The pituitary adenylate cyclase activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: evidence by immunocytochemistry and RT-PCR. Ann NY Acad Sci. 865:147–156. 1998. View Article : Google Scholar : PubMed/NCBI
43.	Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P and Laissue JA: Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60:3105–3112. 2000.
44.	Reubi JC, Körner M, Waser B, Mazzucchelli L and Guillou L: High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 31:803–810. 2004. View Article : Google Scholar : PubMed/NCBI
45.	Gozes I and Furman S: Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract Res Clin Endocrinol Metab. 18:623–640. 2004. View Article : Google Scholar : PubMed/NCBI
46.	Whitmarsh AJ and Davis RJ: Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 74:589–607. 1996. View Article : Google Scholar : PubMed/NCBI
47.	Casibang M, Purdom S, Jakowlew S, Neckers L, Zia F, Ben-Av P, Hla T, You L, Jablons DM and Moody TW: Prostaglandin E₂ and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer. 31:203–212. 2001.
48.	Mankoff DA, O’Sullivan F, Barlow WE and Krohn KA: Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol. 14:398–405. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr, Estes N, DeSimone P and Rayburn P: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photo-scanning. N Engl J Med. 298:1384–1386. 1978. View Article : Google Scholar : PubMed/NCBI
50.	Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM and Becker W: Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 77:787–795. 1998. View Article : Google Scholar : PubMed/NCBI
51.	Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 24:389–427. 2003. View Article : Google Scholar : PubMed/NCBI
52.	Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W and Valent P: Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 33:1116–1121. 1994. View Article : Google Scholar : PubMed/NCBI
53.	Raderer M, Kurtaran A, Hejna M, Vorbeck F, Angelberger P, Scheithauer W and Virgolini I: ^123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer. 78:1–5. 1998. View Article : Google Scholar
54.	Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M, Angelberger P, Kornek G, Pidlich J, Scheithauer W and Virgolini I: Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med. 39:1570–1575. 1998.PubMed/NCBI
55.	Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hübsch P, Dvorak M, Valent P and Niederle B: Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med. 39:1575–1579. 1998.PubMed/NCBI
56.	Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B and Valent P: Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 36:1732–1739. 1995.PubMed/NCBI
57.	Raderer M, Becherer A, Kurtaran A, Angelberger P, Li S, Leimer M, Weinlaender G, Kornek G, Kletter K, Scheithauer W and Virgolini I: Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J Nucl Med. 37:1480–1487. 1996.PubMed/NCBI
58.	Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C, Diggles L, Le Pham H, Ahdoot R and Kalinowski EA: ^99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 41:107–110. 2000.
59.	Pallela VR, Thakur ML, Chakder S and Rattan S: ^99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med. 40:352–360. 1999.
60.	Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C, Diggles L, Pham HL, Ahdoot R, Kalinowski EA and Moody T: Imaging tumors in humans with Tc-99m-VIP. Ann NY Acad Sci. 921:37–44. 2000. View Article : Google Scholar : PubMed/NCBI
61.	Rao PS, Thakur ML, Pallela V, Patti R, Reddy K, Li H, Sharma S, Pham HL, Diggles L, Minami C and Marcus CS: ^99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol. 28:445–450. 2001. View Article : Google Scholar
62.	Kothari K, Prasad S, Korde A, Mukherjee A, Mathur A, Jaggi M, Venkatesh M, Pillai AM, Mukherjee R and Ramamoorthy N: ^99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent. Appl Radiat Isot. 65:382–386. 2007. View Article : Google Scholar
63.	Moody TW, Leyton J, Unsworth E, John C, Lang L and Eckelman WC: (Arg¹⁵, Arg²¹) VIP: evaluation of biological activity and localization to breast cancer tumors. Peptides. 19:585–592. 1998.
64.	Jagoda EM, Aloj L, Seidel J, Lang L, Moody TW, Green S, Caraco C, Daube-Witherspoon M, Green MV and Eckelman WC: Comparison of an ¹⁸F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[¹⁸F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. Mol Imaging Biol. 4:369–379. 2002.
65.	Cheng D, Yin D, Zhang L, Wang M, Li G and Wang Y: Radiosynthesis of ¹⁸F-(R^8,15,21, L¹⁷)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours. Nucl Med Commun. 28:501–506. 2007.
66.	Cheng D, Yin D, Li G, Wang M, Li S, Zheng M, Cai H and Wang Y: Radiolabeling and in vitro and in vivo characterization of [¹⁸F]FB-[R^8,15,21, L¹⁷]-VIP as a PET imaging agent for tumor overexpressed VIP receptors. Chem Biol Drug Des. 68:319–325. 2006.
67.	Chen X, Edwards WB, Anderson CJ, Mccarthy TJ and Welch MJ: Solid phase synthesis of TETA conjugated vasoactive intestinal peptide and in vivo behavior of copper-64 radiolabeled VIP conjugate. J Labelled Compds Radiopharm. 44:S688–S690. 2001. View Article : Google Scholar
68.	Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Prasad S, Wickstrom E and Alavi A: PET imaging of oncogene over-expression using ⁶⁴Cu-vasoactive intestinal peptide (VIP) analog: comparison with ^99mTc-VIP analog. J Nucl Med. 45:1381–1389. 2004.PubMed/NCBI
69.	Zhang K, Aruva MR, Shanthly N, Cardi CA, Rattan S, Patel C, Kim C, McCue PA, Wickstrom E and Thakur ML: PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med. 49:112–121. 2008. View Article : Google Scholar : PubMed/NCBI
70.	Zhang K, Aruva MR, Shanthly N, Cardi CA, Patel CA, Rattan S, Cesarone G, Wickstrom E and Thakur ML: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regul Pept. 144:91–100. 2007. View Article : Google Scholar
71.	Collado B, Carmena MJ, Clemente C, Prieto JC and Bajo AM: Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides. 28:1896–1901. 2007. View Article : Google Scholar : PubMed/NCBI
72.	Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC and Carmena MJ: Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate. 69:774–786. 2009.PubMed/NCBI
73.	Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A and Gozes I: A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA. 90:4345–4349. 1993. View Article : Google Scholar : PubMed/NCBI
74.	Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I and Moody TW: Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56:3486–3489. 1996.PubMed/NCBI
75.	Levy A, Gal R, Granoth R, Dreznik Z, Fridkin M and Gozes I: In vitro and in vivo treatment of colon cancer by VIP antagonists. Regul Pept. 109:127–133. 2002. View Article : Google Scholar : PubMed/NCBI
76.	Moody TW, Jensen RT, Fridkin M and Gozes I: (N-stearyl, norleucine 17) VIP hybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci. 18:29–35. 2002. View Article : Google Scholar : PubMed/NCBI
77.	Moody TW, Leyton J, Coelho T, Jakowlew S, Takahashi K, Jameison F, Koh M, Fridkin M, Gozes I and Knight M: (Stearyl, Norleucine 17) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells. Life Sci. 61:1657–1666. 1997. View Article : Google Scholar : PubMed/NCBI
78.	Zia H, Leyton J, Casibang M, Hau V, Brenneman D, Fridkin M, Gozes I and Moody TW: (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. Life Sci. 66:379–387. 2000. View Article : Google Scholar : PubMed/NCBI
79.	Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, Levy A and Gozes I: VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat. 68:55–64. 2001. View Article : Google Scholar : PubMed/NCBI
80.	Pan CQ, Hamren S, Roczniak S, Tom I and DeRome M: Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line. Peptides. 29:479–486. 2008. View Article : Google Scholar : PubMed/NCBI
81.	Schally AV and Nagy A: Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 15:300–310. 2004. View Article : Google Scholar : PubMed/NCBI
82.	Kim JA: Targeted therapies for the treatment of cancer. Am J Surg. 186:264–268. 2003. View Article : Google Scholar : PubMed/NCBI
83.	Moody TW, Czerwinski G, Tarasova NI and Michejda CJ: VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci. 71:1005–1014. 2002. View Article : Google Scholar : PubMed/NCBI
84.	Moody TW, Czerwinski G, Tarasova NI, Moody DL and Michejda CJ: The development of VIP-ellipticine conjugates. Regul Pept. 123:187–192. 2004. View Article : Google Scholar : PubMed/NCBI
85.	Moody TW, Mantey SA, Fuselier JA, Coy DH and Jensen RT: Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides. 28:1883–1890. 2007. View Article : Google Scholar : PubMed/NCBI
86.	Zaccaro L, Del Gatto A, Pedone C and Saviano M: Peptides for tumour therapy and diagnosis: current status and future directions. Curr Med Chem. 16:780–795. 2009. View Article : Google Scholar : PubMed/NCBI
87.	Tang B, Li Z, Huang D, Zheng L and Li Q: Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library. PLoS One. 8:e542642013. View Article : Google Scholar : PubMed/NCBI
88.	de Visser M, Verwijnen SM and de Jong M: Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm. 23:137–157. 2008.PubMed/NCBI
89.	Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O and Donohoe KJ: Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med. 42:1134–1138. 2001.PubMed/NCBI
90.	Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW and Krenning EP: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 17:R53–R73. 2010. View Article : Google Scholar : PubMed/NCBI